by Silvia Prades | Aug 16, 2023 | News Articles
The FDA, the US regulatory agency for new medicines, declined to review the documents for a potential therapy for SCA3 (type of ataxia) developed by Biohaven. The criteria for approving a drug often rely on standards established for more prevalent conditions, making...
by Silvia Prades | Jul 12, 2023 | Announcements
Rareconnect will retire on 1st December 2023 and we won’t be able to post on the DRPLA community anymore. You can continue getting updates on the following sites:DRPLA Facebook group – https://www.facebook.com/groups/144167217964CureDRPLA Facebook page...
by Silvia Prades | Jul 7, 2023 | Events
Dr Silvia Prades will give an update on the projects funded by CureDRPLA. Followed by a Q&A session with Dr Yael Shiloh-Malawsky from the University of North Carolina and Dr Hector Garcia-Moreno from University College London, experts in DRPLA. This event is...
by Silvia Prades | May 31, 2023 | Announcements
Junko Shiozawa, Advisory Board Member, visited Europe and met with Julie Greenfield, Head of Research at Ataxia UK, to talk about ataxia research and the latest news in DRPLA.
by Silvia Prades | Mar 22, 2023 | News Articles
If you ever asked yourself this, the map we have created will come in handy. We coloured in orange those countries in which at least one person with DRPLA has been identified – 35 countries in total! We have gathered this information from scientific articles and...
Recent Comments